Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 9/20 | 0.54 |
| ▸ | BCR | P11274 | 8/20 | 0.54 |
| ▸ | KIT | P10721 | 5/20 | 0.54 |
| ▸ | BRAF | P15056 | 4/20 | 0.54 |
| ▸ | EGFR | P00533 | 4/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.54 |
| ▸ | LCK | P06239 | 3/20 | 0.54 |
| ▸ | CSF1R | P07333 | 3/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.54 |
| ▸ | FYN | P06241 | 2/20 | 0.54 |
| ▸ | LYN | P07948 | 2/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.54 |
| ▸ | FGR | P09769 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.54 |
| ▸ | NQO2 | P16083 | 2/20 | 0.54 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.54 |
| ▸ | ABL2 | P42684 | 2/20 | 0.54 |
| ▸ | FRK | P42685 | 2/20 | 0.54 |
| ▸ | BLK | P51451 | 2/20 | 0.54 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144678 | 0.94 | HTR2C (0.48) | ABL1BCRKITBRAFEGFR | |
| SCHEMBL4142562 | 0.93 | HTR2C (0.47) | ABL1BCRKITBRAFEGFR | |
| SCHEMBL4132730 | 0.93 | HTR2C (0.47) | ABL1BCRKITBRAFEGFR | |
| SCHEMBL4141772 | 0.92 | ABL1 (0.47) | ABL1BCRKITBRAFEGFR | |
| SCHEMBL4145895 | 0.92 | ADORA2A (0.48) | ABL1BCRKITBRAFEGFR | |
| SCHEMBL4139081 | 0.91 | HDAC1 (0.50) | ABL1BCRKITBRAFEGFR | |
| SCHEMBL4134706 | 0.90 | ABL1 (0.46) | ABL1BCRKITBRAFEGFR | |
| SCHEMBL4144666 | 0.90 | ABL1 (0.47) | ABL1BCRKITBRAFEGFR | |
| SCHEMBL4130570 | 0.89 | SMN1; SMN2 (0.56) | LMNAHDAC1 | |
| SCHEMBL4135613 | 0.89 | ABL1 (0.45) | ABL1BCRKITBRAFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | claimed |
| EP-2134695-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | Exelixis, Inc. (US) | 2009-12-23 | — | — | EP | claimed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | claimed |
| WO-2008112913-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20140309184-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER | UNIVERSITY OF SOUTH ALABAMA (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309184-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER | UNIVERSITY OF SOUTH ALABAMA (US) | 2014-10-16 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-20120238570-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS PATENT COMPANY LLC (US) | 2012-09-20 | — | — | US | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2008112913-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238570-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | SHH, GLI1, SMO | ABL1 1358/4885BCR 1739/4885KIT 177/4885 |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | SHH, GLI1, SMO | ABL1 1257/4885BCR 1622/4885KIT 174/4885 |
| US-20140309184-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER | TP53, ANXA5, VHL | ABL1 286/4885BCR 1510/4885KIT 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.